The

correct answer here is A. Kangalor is the only intravenous P2Y12 inhibitor currently available.

It is a direct-acting intravenous antagonist of the P2Y12 receptor characterized by rapid and potent platelet inhibitory effects with restoration of platelet function occurring within one hour of drug discontinuation.

It also has a very short half-life, about three to six minutes.

Among patients with ACS undergoing PCI who have not received a P2Y12 inhibitor, intravenous Kangalor may be reasonable to reduce periprocedural ischemic events.

This has a class 2B recommendation.

As far as dosing strategy, there's a bolus and an infusion.

And so it's helpful to have an alternative here that can really target high thrombus burdens and or patients who cannot take or absorb their P2Y12 inhibitor in the emergent STEMI setting.

A.

Kangalor is the only intravenous P2Y12 inhibitor currently available.

It is a direct-acting intravenous antagonist of the P2Y12 receptor characterized by rapid and potent platelet inhibitory effects with restoration of platelet function occurring within one hour of drug discontinuation.

It also has a very short half-life, about three to six minutes.

Among patients with ACS undergoing PCI who have not received a P2Y12 inhibitor, intravenous Kangalor may be reasonable to reduce periprocedural ischemic events.

This has a class 2B recommendation.

As far as dosing strategy, there's a bolus and an infusion.

And so it's helpful to have an alternative here that can really target high thrombus burdens and or patients who cannot take or absorb their P2Y12 inhibitor in that emergent STEMI setting.

Eunice, I would love to hear your thoughts on this question.

The correct answer here is B.

In resuscitated patients who are comatose after cardiac arrest, electrically and hemodynamically stable, and without evidence of STEMI, immediate angiography is not recommended due to lack of benefit.

Patients who have been resuscitated after cardiac arrest and are non-comatose or who have comatose with favorable prognostic features and with evidence of STEMI should undergo primary PCI to improve survival.

This is a class one indication.

For patients such as this one, a delayed or selective approach should be taken once the patient is stabilized.

Early angiography should not be denied solely based on a comatose state, but it should be deferred if there are clear non-cardiac causes for the arrest, or if the patient's overall prognosis is futile.

And so it is important to think about these cardiac arrest scores that you outline to try to get some perspective as to whether or not this is a high-risk case.

Younes, I would love to hear your thoughts on this question.

The correct answer here is B.

In resuscitated patients who are comatose after cardiac arrest, electrically and hemodynamically stable and without evidence of STEMI, immediate angiography is not recommended due to lack of benefit.

Patients who have been resuscitated after cardiac arrest and are non-comatose or who have comatose with favorable prognostic features and with evidence of STEMI should undergo primary PCI to improve survival.

This is a class one indication.

For patients such as this one, a delayed or selective approach should be taken once the patient is stabilized.

Early angiography should not be denied solely based on a comatose state, but it should be deferred if there are clear non-cardiac causes for the arrest or if the patient's overall prognosis is futile.

And so it is important to think about these cardiac arrest scores that you outlined to try to get some perspective as to whether or not this is a high-risk case.